Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.12530/24003
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bartley, Angela N | |
dc.contributor.author | Washington, Mary Kay | |
dc.contributor.author | Ventura, Christina B | |
dc.contributor.author | Ismaila, Nofisat | |
dc.contributor.author | Colasacco, Carol | |
dc.contributor.author | Benson, Al B | |
dc.contributor.author | Carrato, Alfredo | |
dc.contributor.author | Gulley, Margaret L | |
dc.contributor.author | Jain, Dhanpat | |
dc.contributor.author | Kakar, Sanjay | |
dc.contributor.author | Mackay, Helen J | |
dc.contributor.author | Streutker, Catherine | |
dc.contributor.author | Tang, Laura | |
dc.contributor.author | Troxell, Megan | |
dc.contributor.author | Ajani, Jaffer A | |
dc.date.accessioned | 2019-06-28T14:03:42Z | - |
dc.date.available | 2019-06-28T14:03:42Z | - |
dc.date.issued | 2016-12 | |
dc.identifier.citation | Am. J. Clin. Pathol..2016 Dec;(146)6:647-669 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12530/24003 | - |
dc.description.abstract | ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA. | |
dc.language.iso | eng | |
dc.rights | openAccess | - |
dc.subject | Gastroesophageal adenocarcinoma | |
dc.subject | Guidelines | |
dc.subject | HER2 testing | |
dc.subject.mesh | Adenocarcinoma | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Esophageal Neoplasms | |
dc.subject.mesh | Esophagogastric Junction | |
dc.subject.mesh | Genetic Testing | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Medical Oncology | |
dc.subject.mesh | Receptor, ErbB-2 | |
dc.subject.mesh | Stomach Neoplasms | |
dc.subject.mesh | United States | |
dc.subject.mesh | Clinical Decision-Making | |
dc.title | HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. | |
dc.type | Artículo | |
dc.identifier.pubmedID | 28077399 | |
dc.format.volume | 146 | |
dc.format.page | 647-669 | |
dc.identifier.e-issn | 1943-7722 | |
dc.identifier.journal | American journal of clinical pathology | |
dc.identifier.doi | 10.1093/ajcp/aqw206 | |
dc.format.number | 6 | |
dc.identifier.pmc | PMC6272805 | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Practice Guideline | |
dc.pubmedtype | Review | |
dc.pubmedtype | Systematic Review | |
Appears in Collections: | Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PMC6272805.pdf | 1.46 MB | Adobe PDF | ![]() View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.